

## COMPANY OVERVIEW

By using the body's immune system, ITUS Corporation is taking multiple approaches to fighting cancer—developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed.

## RECENT NEWS

### Moffitt Cancer Center and ITUS Corporation Announce Scheduling of Pre-IND Meeting with the FDA for their CAR-T Therapy

Sep 5 2018, 7:00 AM EDT

### ITUS Corporation to Present at Next Generation Dx Summit

Aug 17 2018, 7:00 AM EDT

### Moffitt Cancer Center and ITUS Corporation Request Meeting with FDA Regarding Ovarian Cancer CAR-T Therapy

Aug 1 2018, 7:00 AM EDT

## STOCK OVERVIEW

Symbol	ITUS
Exchange	Nasdaq
Market Cap	91.42m
Last Price	\$4.89
52-Week Range	\$1.83 - \$6.43

## INVESTOR RELATIONS

Mike Catelani  
Chief Operating Officer  
T: 408-708-9808  
mcatelani@ituscorp.com

## MANAGEMENT TEAM

### Dr. Amit Kumar, Ph.D

Chairman, President & Chief Executive Officer

### Michael Catelani

Chief Operating Officer and Chief Financial Officer

### John Roop

Senior Vice President of Engineering

### Anthony Campisi

Vice President of Engineering

## ITUS CORPORATION

3150 Almaden Expressway  
Suite 250  
San Jose, CA 95118  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.